e-ISSN 1309-2545      ISSN 1301-062X
TR    ENG
 

Download Current Issue.

Volume : 25 Issue : 3 Year : 2019

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login
Turkish Journal of Neurology Indexed By
 
  Search






Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients [Turk J Neurol]
Turk J Neurol. 2012; 18(1): 17-20 | DOI: 10.4274/Tdn.64325  

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients

Özlem Taşkapılıoğlu, Aslı Bahar Turan, Murat Albas, Ömer Faruk Turan
Department Of Neurology, Uludag University Medical Faculty, Bursa, Turkey

OBJECTIVE: Glatiramer acetate (GA) has been shown to reduce the number of relapses and improve outcomes in relapsing-remitting multiple sclerosis (RRMS) patients. The aim of this study is to investigate the efficacy and side effects of GA in RRMS patients treated with it.
METHODS: We retrospectively reviewed all the records of RRMS patients treated with GA in our hospital from January 1990 to December 2010. We evaluated 114 records but 71 patients (48 women, 23 men) were included in the study due to incompleteness in the other records. Demographic characteristics, time from first symptom to diagnosis, time from diagnosis to treatment, number of relapses and Expanded Disability Status Scale (EDSS) scores before and after the treatment, treatment duration, side effects, the other agents used in MS treatment during the disease duration and the presence of oligoclonal bands were recorded.
RESULTS: The mean age of the patients and mean GA treatment duration were 41,85±9,05 years and 28,73 months, respectively. The mean number of relapses before and after the treatment were 2.30±1.16 and 0,52±1.24 respectively. The number of relapses reduced in 64 (90,14%), unchanged in 4 (5,63%) and increased in 3 (4,23%) patients after GA treatment. The mean EDSS scores before and after the treatment were 2,56±1,46 and 2,04±1,68 respectively. Before GA treatment, 63,4% of all patients had EDSS scores three or more. After the treatment 50,6% of all patients had EDSS scores three or more. GA was the first choice immunomodulatory treatment in 71,8% and the second choice in 28,2% of the patients. The treatment discontinued in 8 (11,3%) patients and the reason was the severe side effect in only one patient (1,4%).
CONCLUSION: Glatiramer acetate decreased the number of relapses and EDSS score with tolerable side effects.

Keywords: Multiple sclerosis, relapsing-remitting, immunomodulatory therapy, glatiramer acetate


Özlem Taşkapılıoğlu, Aslı Bahar Turan, Murat Albas, Ömer Faruk Turan. Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients. Turk J Neurol. 2012; 18(1): 17-20

Corresponding Author: Aslı Bahar Turan, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
© Copyright 2019 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale